Professor of Medicine, University Pennsylvania
Oncology
Dr. Lynn M. Schuchter, MD
|
|
Give Review
Lynn M. Schuchter, MD practices Oncology. She over the years received 6 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FASCO)" and "Super Doctor". Lynn Schuchter is also published. She has 40 publications published. The lastest publication: "Multiple gastrointestinal polyps in patients treated with BRAF inhibitors.' Doctor Lynn M. Schuchter, MD accepts Medicare.
Publications
- Multiple gastrointestinal polyps in patients treated with BRAF inhibitors.
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in Cancer.
- Effects of tailored risk communications for skin Cancer prevention and detection: the PennSCAPE randomized trial.
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
- Ipilimumab-associated Sweet syndrome in a Melanoma patient.
- Characteristics of pyrexia in BRAFV600E/K metastatic Melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial.
- Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma.
- What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing.
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and Melanoma.
- Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and Melanoma.
- Correlation of somatic mutations and clinical outcome in Melanoma patients treated with carboplatin, paclitaxel, and sorafenib.
- Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group...
- Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2.
- Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy.
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma.
- Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas.
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma.
- Physician and Stakeholder Perceptions of Conflict of Interest Policies in Oncology.
- Melanoma Genetic Testing, Counseling, and Adherence to Skin Cancer Prevention and Detection Behaviors.
- Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma.
- Sentinel lymph node biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study.
- Lymphatic Invasion is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma.
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
- Clinical Cancer Advances 2009: major research advances in Cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
- Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other Cancers.
- Drug targeting of oncogenic pathways in Melanoma.
- Clinical Cancer advances 2008: major research advances in Cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
- American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
- A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
- Telomerase-specific T-cell immunity in breast Cancer: effect of vaccination on tumor immunosurveillance.
- Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent Melanoma?
- Adjuvant interferon therapy for Melanoma: high-dose, low-dose, no dose, which dose?
- Retransplantation of a cardiac alloGraft inadvertently harvested from a donor with metastatic melanoma.
- P gene as an inherited biomarker of human eye color.
- Multiple primary Melanoma revisited.
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic Melanoma in the United States.
Schools
Rosalind Franklin University Of Medicine ScienceThe Chicago Medical School
Michael Reese Hospital and Med Center
Johns Hopkins Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
- Super Doctor
Education
-
Johns Hopkins University -
Rosalind Franklin University of Medicine and Science
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center
Drug Facts
| NPI NUMBER | 1285675918 | |
| NPPES Provider LastName | SCHUCHTER | |
| NPPES Provider FirstName | LYNN | |
| NPPES Provider ZIPCode | 191045127 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 115.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 9.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285675918 |
| Last Name Of The Provider | SCHUCHTER |
| First Name Of The Provider | LYNN |
| View All |
Similar Doctors
|
|
Dr. Jonathan D. Cheng, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mina S. Sedrak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander E. Perl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muhammad Rizvi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Holly Dushkin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert F. Ozols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bijoyesh Mookerjee, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Aruna Padmanabhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepthi Subramanya, MD
This Doctor is OpenDoctor Recommended.
|